Steady-state nicotine plasma levels following use of four different types of Swedish snus compared with 2-mg Nicorette chewing gum: A crossover study

Nicotine and Tobacco Research

Volumn 7, Issue 3, 2005, Pages 397-403

  Lunell, Erik ^a,b   Lunell, Marianne ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b CROel AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CATCH DRY MINI; CATCH LICORICE; CATCH MINI; GENERAL; GLYCYRRHIZA EXTRACT; NICOTINE; NICOTINE DERIVATIVE; NICOTINE GUM; PLANT EXTRACT; SODIUM CHLORIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEWING GUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; HEART FAILURE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKELESS TOBACCO; SNUS; STEADY STATE; SWEDEN; TOBACCO DEPENDENCE;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CHEWING GUM; CROSS-OVER STUDIES; HUMANS; MALE; NICOTINE; TOBACCO, SMOKELESS;

EID: 26444470512     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1080/14622200500125468     Document Type: Article

References (20)

1. Andersson, G., Bjornberg, G., & Curvall, M. (1994). Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products; a comparative study. Journal of Oral Pathology and Medicine, 23, 161-167.
2. Asplund, K. (2001). Snus - How dangerous is it? The controversy continues. Journal of Internal Medicine, 250, 457-461.
3. Bates, C., Fagerström, K., Jarvis, M. J., Kunze, M., McNeill, A., & Ramström, L. (2003). European Union policy on smokeless tobacco. A statement in favour of evidence-based regulation for public health. Tobacco Control, 2003, 12, 360-367.
4. Benowitz, N. L., Jacob, P. III, & Savanapridi, C. (1987). Determinants of nicotine intake while chewing nicotine polacrilex gum. Clinical Pharmacology and Therapeutics, 41, 467-473.
5. Bolinder, G. M., Ahlborg, B. O., & Lindell, J. H. (1992). Use of smokeless tobacco: Blood pressure elevation and other health hazards found in a large-scale population survey. Journal of Internal Medicine, 232, 327-334.
6. Bolinder, G. M., & de Faire, U. (1998). Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users. American Journal of Hypertension, 11, 1153-1163.
7. Brunneman, K. D., & Hoffmann, D. (1993). Chemical composition of smokeless tobacco products. In: Smokeless tobacco or health: An international perspective (Smoking and Tobacco Control Monograph Number 2, pp. 96-106). Bethesda, MD: U.S. Department of Health and Human Services.
8. Brunneman, K. D., Qi, J., & Hoffmann, D. (2001). Aging of oral moist snuff and the yields of tobacco specific N-nitrosamines (TSNA). Progress report prepared for the Massachusetts Tobacco Control Program. Department of Public Health, Boston, Massachusetts. Retrieved January 18, 2005, from http://www.tobacco.org/news/010622bostonre.html
9. Critchley, J. A., & Unal, B. (2003). Health effects associated with smokeless tobacco: A systematic review. Thorax, 58, 435-443.
10. Fant, R. V., Henningfield, J. E., Nelson, R. A., & Pickworth, W. B. (1999). Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tobacco Control, 8, 387-392.
11. Feyerabend, C., & Russell, M. A. H. (1990). A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. The Journal of Pharmacy and Pharmacology, 42, 450-452.
12. Foulds, J., Ramstrom, L., Burke, M., & Fagerström, K. (2003). The effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tobacco Control, 12, 349-359.
13. Holm, H., Jarvis, M. J., Russell, M. A., & Feyerabend, C. (1992). Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology, 108, 507-511.
14. Kozlowski, L. T., O'Connor, R. J., & Edwards, B. Q. (2003). Some practical points on harm reduction: What to tell your lawmaker and what to tell your brother about Swedish snus. Tobacco Control, 12, 372-373.
15. Larsson, I., Curvall, M., & Enzell, C. R. (1987). Disposition of nicotine and cotinine in plasma, saliva and urine of snuff-users. Proceedings from the third European Congress of Biopharmaceutics and Pharmacokinetics, pp. 318-324.
16. Lindström, M., & Isacsson, S.-O. (2001). The Malmö shoulder-neck study group. Smoking cessation among daily smokers, aged 45-69 years: A longitudinal study in Malmö, Sweden. Addiction, 97, 205-215.
17. Rodu, B., & Cole, P. (2002). Smokeless tobacco use and cancer of the upper respiratory tract. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodonties, 5, 511-515.
18. Schneider, N. G., Olmstead, R. E., Franzon, M. A., & Lunell, E. (2001). The nicotine inhaler. Clinical pharmacokinetics and comparison with some other nicotine treatinents. Clinical Pharmacokinetics, 40, 661-684.
19. Tomar, S. L., Connolly, G. N., Wilkenfeld, J., & Henningfield, J. E. (2003). Declining smoking in Sweden: Is Swedish Match getting the credit for Swedish tobacco control's efforts? Tobacco Control, 12, 368-371.
20. World Health Organization. (1997). Tobacco or health: A global status report. Geneva, Switzerland: Author.